Editas Medicine Makes New Appointments
This article was originally published in Scrip
Genome editing company, Editas Medicine, has appointed Timothy D. Hunt senior vice president of corporate affairs and Haiyan Jiang vice president of preclinical science. Hunt joins Editas from Cubist Pharmaceuticals where he was senior vice president of public affairs, before it was acquired by Merck last year. Jiang started her career as a scientist at Avigen and before joining Editas, she was senior director of cell and gene therapy at Biogen.